Abeona Therapeutics (NASDAQ:ABEO) Director Christine Berni Silverstein Sells 18,160 Shares of Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Christine Berni Silverstein sold 18,160 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $5.71, for a total transaction of $103,693.60. Following the transaction, the director owned 119,562 shares in the company, valued at $682,699.02. This represents a 13.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abeona Therapeutics Stock Up 2.5%

Abeona Therapeutics stock opened at $5.67 on Tuesday. The firm has a market capitalization of $323.13 million, a PE ratio of 5.85 and a beta of 1.35. The company’s 50-day moving average is $5.45 and its 200-day moving average is $5.19. Abeona Therapeutics Inc. has a fifty-two week low of $4.00 and a fifty-two week high of $7.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.89 and a quick ratio of 5.70.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The company had revenue of $8.72 million for the quarter, compared to the consensus estimate of $4.57 million. Sell-side analysts anticipate that Abeona Therapeutics Inc. will post -0.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Oppenheimer reaffirmed an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a research report on Tuesday, March 17th. Finally, Wall Street Zen raised Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Abeona Therapeutics currently has an average rating of “Hold” and an average target price of $19.00.

Institutional Trading of Abeona Therapeutics

Several large investors have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Abeona Therapeutics by 49.6% during the 1st quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 2,155 shares in the last quarter. Legato Capital Management LLC lifted its stake in Abeona Therapeutics by 21.0% in the 4th quarter. Legato Capital Management LLC now owns 13,180 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 2,290 shares during the last quarter. Deutsche Bank AG lifted its stake in Abeona Therapeutics by 6.2% in the 4th quarter. Deutsche Bank AG now owns 39,368 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 2,303 shares during the last quarter. Rangeley Capital LLC lifted its stake in Abeona Therapeutics by 4.2% in the 1st quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 2,400 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in Abeona Therapeutics by 5.3% in the 4th quarter. LPL Financial LLC now owns 62,873 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 3,165 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.